PL1734996T3 - Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5 - Google Patents

Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5

Info

Publication number
PL1734996T3
PL1734996T3 PL05763460T PL05763460T PL1734996T3 PL 1734996 T3 PL1734996 T3 PL 1734996T3 PL 05763460 T PL05763460 T PL 05763460T PL 05763460 T PL05763460 T PL 05763460T PL 1734996 T3 PL1734996 T3 PL 1734996T3
Authority
PL
Poland
Prior art keywords
integrin
beta
alpha
compositions
treating
Prior art date
Application number
PL05763460T
Other languages
English (en)
Polish (pl)
Inventor
Dean Sheppard
Amha Atakilit
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PL1734996T3 publication Critical patent/PL1734996T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL05763460T 2004-04-02 2005-03-30 Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5 PL1734996T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55917504P 2004-04-02 2004-04-02
PCT/US2005/011222 WO2005094391A2 (en) 2004-04-02 2005-03-30 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN
EP05763460.2A EP1734996B1 (en) 2004-04-02 2005-03-30 Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin

Publications (1)

Publication Number Publication Date
PL1734996T3 true PL1734996T3 (pl) 2013-09-30

Family

ID=35064346

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05763460T PL1734996T3 (pl) 2004-04-02 2005-03-30 Sposoby i kompozycje do leczenia i profilaktyki choroby związanej z integryną alfa v beta 5

Country Status (14)

Country Link
US (2) US20050226865A1 (enExample)
EP (2) EP2394662B1 (enExample)
JP (2) JP5223072B2 (enExample)
CN (1) CN1964740A (enExample)
AU (1) AU2005229015C1 (enExample)
CA (1) CA2562038C (enExample)
CY (1) CY1114497T1 (enExample)
DK (1) DK1734996T3 (enExample)
ES (2) ES2671522T3 (enExample)
HR (1) HRP20130782T1 (enExample)
PL (1) PL1734996T3 (enExample)
PT (1) PT1734996E (enExample)
RS (1) RS52918B (enExample)
WO (1) WO2005094391A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2456460A4 (en) * 2009-07-24 2013-02-20 Univ California METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN
WO2013181666A2 (en) * 2012-06-01 2013-12-05 Isis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
MX2015011670A (es) * 2013-03-15 2016-03-31 Biogen Ma Inc Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
WO2014144616A2 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 5 antibodies and uses thereof
EP3021942A4 (en) * 2013-07-19 2017-04-19 The Regents of The University of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
MX2017003014A (es) * 2014-09-12 2017-05-30 Biogen Ma Inc Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023A (en) * 1853-09-20 Machine fob sawing sticks eob broom-handles
US171271A (en) * 1875-12-21 Improvement in bob-sleds
US72500A (en) * 1867-12-24 Improvement in bleaceisg and scouring hemp, flax, aid other fibres
US139398A (en) * 1873-05-27 Improvement in lamp-extinguishers
US181440A (en) * 1876-08-22 Improvement in steam-boiler furnaces
US37889A (en) * 1863-03-10 Mode of
US19035A (en) * 1858-01-05 mallary
US19037A (en) * 1858-01-05 Washing-machine
US18192A (en) * 1857-09-15 And samuel m
US19206A (en) * 1858-01-26 Hydrant
US77321A (en) * 1868-04-28 Amos bank
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5231114A (en) 1990-06-22 1993-07-27 Wakunaga Seiyaku Kabushiki Kaisha Polysulfides compounds and lipid peroxidation inhibitor containing the polysulfide compounds as active ingredient
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5527679A (en) * 1991-05-01 1996-06-18 Dana Farber Cancer Institute β5 protein and DNA encoding the same
DE4142366A1 (de) * 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6291196B1 (en) * 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
CA2131389A1 (en) 1992-03-02 1993-09-16 John M. Maraganore Thrombin receptor antagonists
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US7053041B1 (en) * 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
DE69635417T2 (de) * 1995-08-14 2006-07-13 The Scripps Research Institute, La Jolla VERFAHREN UND MITTEL ZUR HEMMUNG DER DURCH ALPHA v BETA 5 VERMITTELTEN ANGIOGENESE
JP2002504086A (ja) 1996-05-01 2002-02-05 イーライ・リリー・アンド・カンパニー Ｖｅｇｆ関連疾患の治療的処置
ES2286834T5 (es) 1996-08-12 2011-01-31 Mitsubishi Tanabe Pharma Corporation Medicamentos que comprenden un inhibidor de la rho quinasa.
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US20020004482A1 (en) * 1997-08-08 2002-01-10 Xiaozhu Huang Treatment of acute lung injury and fibrosis with antagonists of avbeta6
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
EP1140205A2 (en) 1998-12-30 2001-10-10 Edema Clearance, Inc. GENE THERAPY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING Na,K-ATPase
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6399581B1 (en) 1999-05-11 2002-06-04 Harbor Branch Oceanographic Institution, Inc. Compound possessing potent thrombin receptor antagonist activity
DE60021521T4 (de) 1999-09-29 2006-09-21 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamide zur behandlung von integrin vermittelten störungen
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6544982B1 (en) 1999-10-29 2003-04-08 Merck & Co., Inc. Thrombin receptor antagonists
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU780364B2 (en) 2000-01-20 2005-03-17 Merck Sharp & Dohme Corp. Alpha V integrin receptor antagonists
CA2397665A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US6515023B2 (en) 2000-01-31 2003-02-04 Merck & Co., Inc. Thrombin receptor antagonists
US6403612B2 (en) 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
ES2341843T3 (es) 2000-02-03 2010-06-29 EISAI R&D MANAGEMENT CO., LTD. Inhibidores de la expresion de integrina.
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
JP2001320372A (ja) 2000-03-13 2001-11-16 Hyundai Electronics Ind Co Ltd 統合インターネットプロトコル網で統合加入者サーバの機能的モデリングを通した統合加入者管理装置及びその方法
WO2001078790A2 (en) 2000-04-18 2001-10-25 Edema Clearance, Inc. GENE THERAPHY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING A β2ADRENERGIC RECEPTOR GENE
EP1289960A2 (en) 2000-06-15 2003-03-12 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
US20020072500A1 (en) 2000-09-27 2002-06-13 Thomas Rogers Hydroxy acid integrin antagonists
JP2004513953A (ja) 2000-10-24 2004-05-13 メルク　エンド　カムパニー　インコーポレーテッド ジベンズオキサゼピンαＶインテグリン受容体アンタゴニスト
CA2433680A1 (en) 2000-12-28 2002-08-01 Gregory M Arndt Double-stranded rna-mediated gene suppression
JP2005506524A (ja) 2001-04-04 2005-03-03 アラーガン、インコーポレイテッド 血管新生の阻害剤をスクリーニングおよび使用する方法
US7081460B2 (en) 2001-04-09 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
US20040019206A1 (en) 2001-09-27 2004-01-29 Peter Ruminiski Lactone integrin antagonists
DK1539739T3 (da) * 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
US20040266755A1 (en) 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Also Published As

Publication number Publication date
ES2411965T3 (es) 2013-07-09
JP5681149B2 (ja) 2015-03-04
JP2007531733A (ja) 2007-11-08
EP2394662B1 (en) 2018-03-21
WO2005094391A2 (en) 2005-10-13
ES2671522T3 (es) 2018-06-06
US20050226865A1 (en) 2005-10-13
AU2005229015A1 (en) 2005-10-13
AU2005229015B2 (en) 2012-08-30
CA2562038C (en) 2017-04-25
HK1098077A1 (en) 2007-07-13
WO2005094391A3 (en) 2005-12-01
PT1734996E (pt) 2013-07-18
CN1964740A (zh) 2007-05-16
EP2394662A2 (en) 2011-12-14
EP1734996A4 (en) 2008-09-10
HRP20130782T1 (en) 2013-09-30
EP2394662A3 (en) 2012-02-22
RS52918B (sr) 2014-02-28
CA2562038A1 (en) 2005-10-13
DK1734996T3 (da) 2013-06-10
EP1734996B1 (en) 2013-05-22
CY1114497T1 (el) 2016-10-05
EP1734996A2 (en) 2006-12-27
JP2013028611A (ja) 2013-02-07
US7815908B2 (en) 2010-10-19
US20090280118A1 (en) 2009-11-12
AU2005229015C1 (en) 2013-01-17
JP5223072B2 (ja) 2013-06-26

Similar Documents

Publication Publication Date Title
SI1771201T1 (sl) Sestavki in metode za zdravljenje ali preprečevanje z oksalatom-povezanih bolezni
PL1965816T3 (pl) Kompozycje farmaceutyczne i sposoby leczenia lub zapobiegania chorobom związanym ze szczawianami
PL1920065T3 (pl) PRZECIWCIAŁA ANTY-αvβ6 I ICH ZASTOSOWANIA
IL178390A0 (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
TWI348891B (en) Composition for preventing plant diseases and method for preventing the diseases
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
EP1944277A4 (en) ANTI-ARTICLE AND ANTIBACITY COMPOSITION
EP1589996A4 (en) ANTI-INTEGRIN ALPHA BETA 3 ANTIBODY FORMULATIONS AND ITS USES
IL191884A0 (en) Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same
EP1668024A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INCLUDING INFLAMMATORY SUFFERING
IL187620A0 (en) 17??-hsd1 and sts inhibitors
EP1545578A4 (en) COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES
EP1512415A4 (en) LURE COMPOSITION FOR TREATING AND PREVENTING INFLAMMATORY DISEASES
LT1921077T (lt) Agentas, skirtas miego sutrikimo gydymui ir (arba) prevencijai
ZA200707407B (en) Composition for preventing plant diseases and method for preventing the diseases
AU2003212850A8 (en) Methods and compositions for treating cardiovascular disease
PL1908779T3 (pl) Pochodne tymozyny beta 4 i ich zastosowanie
PL1762219T3 (pl) Fotoochronne i/lub fotoimmunoochronne kompozycje do skóry i ich zastosowania
HRP20130782T1 (en) Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
IL178598A0 (en) Skin-protecting alkalinity-controlling composition and the use thereof
SI1734996T1 (sl) Postopki in sestavki za zdravljenje in preprečevanje bolezni, povezane z integrinom alfa v beta 5
EP1807067A4 (en) SPHINGOSINKINASE ACTIVATOR AND TREATMENT AGENT FOR SKIN DISEASES THEREWITH
EP1850827A4 (en) COMPOSITION FOR TREATING AND PREVENTING PERIODONTAL DISEASE AND USE METHOD
EP1660114A4 (en) METHOD AND COMPOSITIONS FOR TREATING DYSFUNCTIONS OF THE EXTRACELLULAR MATRIX
EP1829860A4 (en) 9,10-SECOPREGNANDERIVAT AND MEDICINE